Revco Corporation purchases 35 percent of the voting stock of Ronco Pharmaceuticals on January 1, 2022, for $15 million in cash. Ronco's book value at the date of acquisition is $10 million. Investigation reveals that Ronco's reported patents (10-year life) are undervalued by $2 million and it has unreported technology (5-year life) valued at $4 million. Ronco pays dividends of $300,000 and reports net income of $1,500,000 for 2022. Required Prepare the journal entries on Revco's books to report the above information assuming Revco accounts for its investment in Ronco using the equity method. Date 01/01/22 12/31/22 Description To record dividends reported by Ronco. Debit Credit To record net income reported by Ronco. At what amount does Revco report the investment in Ronco on its December 31, 2022, balance sheet?